Inventiva announces FDA has granted Breakthrough Therapy designation to lanifibranor in NASH
- NEWS RELEASE
Inventiva (France) announced on 12 October, 2020, FDA haas granted Breakthrough Therapy designation to lanifibranor for the treatment of NASH.
For detailed information, see the below URL.
Lanifibranor is a PPAR agonist with moderate and well-balanced activity on the three PPAR isoforms (a, g, σ) This compound is also currently undergoing Phase 2 trials.
We are looking forward to future clinical results.